It needs to be reconstituted, dissolved into solution, before administration
Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
These regulate various processes in the body such as growth, digestion, immunity, and many others
Slowly depress the plunger so the water trickles down the inside wall of the vial
Evidence-based levers that reliably move the needle: Weight Loss Programs A good rule of thumb: do not outsource a fundamentals problem to an unproven tool
It is investigational and is being studied in Eli Lilly's Phase 3 TRIUMPH (obesity-focused) and TRANSCEND-T2D (type 2 diabetes) programs